The XORTX team of multi-disciplinary industry professionals is capable of drug development from discovery to marketing approval. Over 60 years of manufacturing, clinical and regulatory drug development experience.
Recent human studies have defined a role for chronically increased serum uric acid (SUA) in a disease axis that includes rare-”orphan” diseases, such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, blood pressure, kidney injury, diabetes, and diabetic nephropathy. Stll more recent human studies have shown that decreasing and maintaining lower uric acid levels using..More
XORTX Patents and patent applications claim the use of and composition of uric acid lowering agents for the treatment of hypertension, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy and other diseases.
Latest Press Releases
XORTX Pharma Corp. – a company focused on the development of drugs to treat orphan and non-orphan kidney diseases – is...
Calgary – November 28, 2014 – XORTX Pharma Corp. Announces Addition of Mr. Bruce Rowlands to the XORTX Board of Directors Board
XORTX Pharma Corp. is pleased to announce the appointment of Mr. Bruce Rowlands to the XORTX Board of Directors, effective November...
Bradmer Pharmaceuticals Inc. Announces Proposed Reverse Take-Over Transaction With XORTX Pharma Corp.